Regional anaesthesia for orthopaedic procedures

Regional anaesthetic techniques are fundamental in the anaesthetic care of orthopaedic patients. They may be used as the primary anaesthetic technique or to provide postoperative pain relief. Compared to general anaesthesia alone, regional techniques can provide superior perioperative analgesia, fewer systemic drug adverse effects such as nausea, vomiting and confusion, and earlier mobilization which can reduce nosocomial complications and facilitate expedited hospital discharge. Disadvantages include block failure, nerve injury, unrecognised injury to the anaesthetised limb, prolonged motor blockade and local anaesthetic toxicity. Preoperative assessment should identify contraindications, document pre-existing neurological deficits, and clarify surgical and perioperative aims. Informed consent should be obtained after a clear explanation of the procedure, its risks, and potential complications. Serious and long-term neurological complications are rare and may be reduced by an awake regional technique, sonographic guidance, regular aspiration and by ensuring low pressure injections. Postoperative follow-up is essential and suspicious neurological findings should be detected, investigated, and managed in an early and timely manner.     

Adjuvant agents in regional anaesthesia

The addition of adjuvant agents to intrathecal and epidural anaesthetic techniques is well established, in particular opioids and clonidine. These adjuvants are utilized to improve the quality of anaesthesia and analgesia. Several other adjuvants have been studied but ongoing concerns surrounding safety and efficacy may limit their use in clinical practice. Epinephrine has for many years been administered in combination with local anaesthetic although more recently a diverse range of adjuvants have been added to peripheral nerve block solutions, again with the aim of prolonging surgical anaesthesia. The evidence to support or refute the benefit of these agents is increasing, as is our understanding of which agents have demonstrable efficacy and safety at clinically appropriate doses. Clinicians must be aware that many adjuvants are not licensed for central neuraxial or perineural use and should be aware of the risks, in particular of neurotoxicity and unwanted side effects.     

DSA引导下腰交感神经阻滞治疗妇科肿瘤术后下肢淋巴水肿

目的观察DSA引导下腰交感神经阻滞治疗妇科肿瘤术后下肢淋巴水肿的有效性及安全性。方法回顾性分析20例妇科肿瘤术后下肢淋巴水肿患者,均接受DSA引导下腰交感神经阻滞治疗(均治疗2次)。分别于阻滞前、首次阻滞后第1天及第2次阻滞后第1、7天测量患侧腿围,记录患侧腿围缩小值。采用Inbody720多频生物电阻人体成分分析仪检测阻滞前及第2次阻滞后1周时的组织水肿程度;观察症状改善及功能恢复情况。结果 20例均顺利完成阻滞。1例术后出现短暂下肢无力,余无不良反应。首次阻滞后第1天及第2次阻滞后第1、7天患侧下肢各测量点腿围均不同程度缩小,且各测量点第2次阻滞术后第1、7天腿围缩小值均高于第1次术后第1天(P均0.01)。第2次阻滞后1周组织水肿程度较术前降低(P0.01),髋关节活动度较术前增加(P0.01),患侧下肢肿胀感、紧绷感、疼痛感、麻木感均消失。结论 DSA引导下腰交感神经阻滞治疗妇科肿瘤术后下肢淋巴水肿有效且安全。     

内镜下全腹膜外Sublay修补在腹壁疝中的应用

目的评价腹壁疝内镜下全腹膜外Sublay(TES)手术的效果并总结经验。方法回顾性总结国内10所医院自2016年3月至2019年7月115例腹壁疝内镜下TES手术的患者资料。分析患者情况、疝的特点、手术经过和结果。结果115例计划实施TES的患者中,因严重腹膜破损中转为IPOM修补患者1例,其余均成功手术。可以缝合缺损患者108例(94.74%),需要永久补片固定患者15例(13.16%)。放置引流患者76例(66.67%),中位手术时间为144 min,术中无严重并发症发生。随访时间3~45个月,总并发症发生率为20例(17.54%),其中出现血清肿患者5例(4.38%)。绝大多数患者术后仅出现轻微疼痛,未出现慢性疼痛。结论在腹壁疝的治疗中,对熟悉腹壁解剖的外科医师而言,TES是一种有效、安全的修复手段。在熟悉手术的基础上适应症可逐步拓展。     

The association between caudal block and urethroplasty complications of distal tubularized incised plate repair: experience from a South China National Children’s Medical Center

BackgroundThe effect of caudal block (CB) on the incidence of urethroplasty complications in hypospadias repair remains controversial. The evidence is conflicting, and some confounding bias issues need to be addressed. We sought to study a more homogenous group of distal hypospadias patients undergoing primary tubularized incised plate (TIP) repair by a senior pediatric urology surgeon in the past 2 years to examine the relationship between urethroplasty complications and the use of CB.MethodsWe reviewed our database to identify consecutive patients who had undergone hypospadias repairs by a senior director surgeon at our Center between January 2018 and November 2020. To be eligible to participate in the study, patients had to meet the following inclusion criteria: (I) have distal hypospadias; (II) have undergone a primary TIP repair; and (III) have attended follow-up appointments for a minimum period of 6 months. The primary outcome was the development of urethroplasty complications during the follow-up period. The principal variable of interest was whether or not CB was used perioperatively. The patients were categorized into a CB group (general anesthesia combined with CB) or a control group (general anesthesia only). Other potential risk factors were analyzed, including patient age at operation, patient weight, glans width, and the length of the urethral plate defect.ResultsThirty (12.2%) of the distal patients developed postoperative surgical complications. The postoperative surgical complication rates were similar between the different anesthesia groups. Weight, the length of the urethral plate length, and glans width did not contribute to the risk. Age was the only independent risk factor for postoperative surgical complications, and the complication rates increased in older patients.ConclusionsOur data from consecutive TIP repairs in distal hypospadias patients indicated no association between the use of CB anesthesia and the postoperative urethroplasty complication rate. Patients who were older in age when they underwent surgery had a higher risk of complications.     

不同年龄组正常人群影响最大胸椎后凸角的相关因素分析

目的：本研究通过对不同年龄组正常人群矢状位参数进行分析,旨在报道正常人群脊柱骨盆参数参考值范围,并探索不同年龄段引起最大胸椎后凸角改变的影响因素。 方法：本研究纳入自2015年1月至2018年月于两所医院健康体检中心的正常人群,收集人口统计学参数以及矢状位影像学参数。通过将人群分为≤40岁组与＞40岁组,对比分析不同年龄组人群的矢状位参数,并对不同年龄组影响最大胸椎后凸角max TK的因素进行相关性分析。结果：本研究共计纳入191例正常人群,其中≤40岁组94人,平均年龄为28.5±6.4岁;＞40岁组97人,平均年龄为53.9±8.3岁。不同年龄组人群在胸1椎体矢状位倾斜角T1 Tilt（18.6±6.5 vs. 20.6±5.5, P=0.023）, 胸椎后凸下端椎倾斜角TVA（15.3±5.3 vs. 17.5±6.6, P=0.013）,max TK（33.9±8.3 vs. 38.0±9.4, P<0.001）,max LL- max TK（14.9±8.9 vs. 12.3±9.4, P=0.048）及矢状面躯干偏移SVA（-2.5±21.8 vs. 6.1±20.9, P=0.006）上存在显著差异。在年龄≤40岁的人群中,T1 Tilt、TVA、max LL及骶骨倾斜角SS与max TK显著相关,而在年龄＞40岁的人群中,年龄、T1 Tilt、TVA、max LL及骨盆入射角PI与max TK显著相关。结论：max TK随着年龄增长呈现上下均匀增长趋势,在＞40岁的人群中,max TK与年龄呈现正相关关系。此外,不同年龄阶段,骨盆对于max TK改变的代偿呈现出不同的模式。     

近端联合远端收肌管阻滞在全膝关节置换术患者术后镇痛和早期功能康复中的应用

目的 探讨近端联合远端收肌管阻滞在全膝关节置换术患者术后镇痛和早期功能康复中的应用。方法 选取2019年1月至2020年12月在解放军总医院第六医学中心择期行单侧全膝关节置换术患者90例,按随机数字表法分为3组,每组30例。A组为对照组,于超声引导下行股神经联合腘窝上坐骨神经阻滞;B组为近端联合远端收肌管阻滞组,于超声引导下分别行收肌管近端和远端阻滞;C组为右美托咪定联合收肌管阻滞组,于超声引导下将罗哌卡因与右美托咪定混合液分别注射至收肌管近端和远端。比较3组患者术后6 h(T₁)、12 h(T₂)、24 h(T₃)和48 h(T₄)时静息VAS评分,术后T₃和T₄时运动VAS评分,48 h内羟考酮和氟比洛芬酯使用情况;以及术后24 h(T₃)、48 h(T₄)和72 h(T₅)膝关节活动范围(ROM)和股四头肌肌力;记录3组患者术后首次直腿抬高≥10 cm时间,术后首次下床活动时间,术后7...     

Ca2+ channel actions of the non-dihydropyridine Ca2+ channel antagonist Ro 40-5967 in vascular muscle cells cultured from dog coronary and saphenous arteries

Summary We studied the membrane effects of (1S,2S)-2-(2-[[3-2(benzimidazolyl) propyllmethylamino]ethyl)-6-fluoro-1,2,3,4-tetrahydro-l-isopropyl-2-naphthyl-methoxy-acetate dihydrochloride, Ro 40-5967, a new non-dihydropyridine (DHP) Ca²⁺ channel antagonist, on dog coronary and saphenous arterial vascular muscle cells using the whole-cell patch-clamp method. Long-lasting (L-type) inward currents in 20 mM Ba²⁺ were measured over a range of test potentials (300 ms) from –50 mV to + 90 mV from a holding potential of –80 mV in the presence of 1 M Bay k8644 (a DHP Ca²⁺ agonist). Ro 40-5967 caused a concentration-dependent suppression of Ca²⁺ channel currents in muscle cells from both arteries, with greater potency on coronary than saphenous arterial cells. The concentration of Ro 40-5967 which inhibited the magnitude of peak inward currents by 50% (IC₅₀) was estimated to be 1 M (n = 5) in muscle cells from coronary artery and 10 M (n = 4) in saphenous artery. Ro 40-5967 (1 M) decreased the amplitude of the activation current-voltage relationship for coronary L-type Ca²⁺ channel currents over a wider range of membrane potentials than verapamil, diltiazem, or nifedipine. In contrast, block of Ca²⁺ channel currents in saphenous artery cells by 1 M Ro 40-5967 was only observed at command potentials positive to 0 mV. Ro 40-5967 (1 M) significantly shifted the voltage-inactivation curve downward by 40% in coronary (n = 4), but only by 18% in saphenous arterial muscle cells (n = 3). The non-parallel shift of the coronary artery inactivation curve suggests that pronounced resting channel block is a notable feature of Ro 40-5967. The marked inhibition of Ba²⁺ current by 1 M Ro 40-5967 in the inactivation protocol in coronary arterial muscle cells was found over the entire range of membrane holding potentials tested, while inhibition in the saphenous artery inactivation curve occurred only from holding potentials more positive than –40 mV. Therefore, Ro 40-5967 is unique: 1) in acting over a wider range of voltages, on both instantaneous and resting Ca²⁺ currents, than other Ca²⁺ antagonists; 2) in producing more significant resting state block; and 3) in acting with selectivity for coronary over saphenous arteries.This research was supported by National Institutes of Health grants HL38537, HL38645, and by F. Hoffmann-La Roche, Basel, Switzerland